From Gut to Skin: How Early-Life Microbiome Development Shapes the Atopic March

The relationship between gut microbiome composition and skin health is increasingly well-supported by research — yet translating this science into clinical practice remains a challenge for many practitioners. In this session, we build on foundational gut–skin axis knowledge to explore how early-life microbiome development shapes immune programming, establishes the trajectory for atopic disease and how these insights can be translated into clinical care.

Focusing on the atopic march — the progression from eczema in infancy through food allergies, allergic rhinitis, and asthma — this session explores how early microbial patterns influence immune tolerance, inflammation, and barrier function across the gut–skin axis. Particular attention is given to the role of Bifidobacterium in early immune education, the distinct microbiome signatures associated with birthing methods, and the downstream effects of common disruptors including formula feeding and antibiotic exposure. Research from the Infant Restore randomized controlled trial is presented as clinical evidence of how microbiome-guided interventions can recover the microbial community and improve gut-skin-immune outcomes for infants.

The session concludes by briefly extending these principles beyond infancy, emphasizing how shotgun metagenomic testing can be used to assess gut–skin-immune interactions and guide personalized care across all patient populations.

Learning Objectives:

By the end of this session, participants will be able to:

• Explain how early-life microbiome development influences immune programming and impacts skin health through the gut–skin axis
• Describe the atopic march and the role of early microbial patterns and disruptions in driving progression from eczema to allergic disease
• Identify key microbial features associated with atopic risk — including Bifidobacterium depletion and C-section-associated dysbiosis — and their effects on immune tolerance, inflammation, and barrier function
• Apply microbiome-informed strategies, including stool testing and targeted interventions, to assess and support patients with atopic and inflammatory skin conditions across the lifespan